We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Theratechnologies Inc (TH) COM NPV

Sell:1.85 CAD Buy:1.90 CAD Change: No change
Market closed |  Prices as at close on 16 August 2024 | Switch to live prices |
Sell:1.85 CAD
Buy:1.90 CAD
Change: No change
Market closed |  Prices as at close on 16 August 2024 | Switch to live prices |
Sell:1.85 CAD
Buy:1.90 CAD
Change: No change
Market closed |  Prices as at close on 16 August 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

Contact details

Address:
2015 Peel Street, 11th Floor
MONTREAL
H3A 1T8
Canada
Telephone:
+1 (514) 3367800
Website:
https://www.theratech.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
TH
ISIN:
CA88338H7040
Market cap:
86.05 million CAD
Shares in issue:
45.98 million
Sector:
Biotechnology
Exchange:
Toronto Stock Exchange
Country:
Canada
Currency:
Canadian dollars
Indices:
n/a

Key personnel

  • Paul Levesque
    President, Chief Executive Officer, Director
  • Philippe Dubuc
    Chief Financial Officer, Senior Vice President
  • Christian Marsolais
    Senior Vice President, Chief Medical Officer
  • Marienoel Colussi
    Vice President - Finance
  • Andre Dupras
    Vice President of Human Resources
  • Jocelyn Lafond
    General Counsel, Company Secretary
  • John Leasure
    Global Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.